Truist Securities Assumes Rapport Therapeutics at Buy, Raises Price Target to $56
Benzinga Newsdesk 5 months ago
NewsPrice TargetInitiationAnalyst Ratings
Truist Securities analyst Danielle Brill assumes Rapport Therapeutics (NASDAQ:RAPP) with a Buy rating and raises Price Target to $56.
Truist Securities analyst Danielle Brill assumes Rapport Therapeutics (NASDAQ:RAPP) with a Buy rating and raises Price Target to $56.